Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Localization of ferritin with immunohistochemical staining was carried out in thirty six cases of malignant histiocytosis (MH). The positivity rate for ferritin was 100 per cent. Ferritin was found to exist in the cytoplasm of the tumor cells. Image analysis showed that ferritin level in the well-differentiated histiocytes (1.2314) was higher than that in the atypical histiocytes (0.7181) (P < 0.01). Ten MH patients showed surprising high serum ferritin concentration (1482.3 ng/ml) than that in normal. Our data suggest that ferritin is the tumor associated antigen in MH. The synthesis and release of ferritin by MH tumor cells is the important cause for the high concentration of serum ferritin in patients.
Zhonghua Nei Ke Za Zhi 1992 Dec
PMID:[Immunohistochemical localization and serum testing for ferritin in malignant histiocytosis]. 130 85

Erythrocyte basic ferritin (EF) concentration was determined in 64 normal subjects, 123 patients with anemia and 12 patients with leukopenia and thrombocytopenia. There was a significant difference between males and females. Other iron indices, including plasma iron (PI), total iron binding capacity (TIBC), zinc protoporphyrin (ZnPP) and plasma ferritin (PF) were also determined in all the subjects and bone marrow iron stain was determined in the 135 patients. The lowest EF concentration was seen in patients with iron deficiency anemia, being significantly lower than that in normal subjects. EF concentration in patients with iron deficiency erythropoiesis was also lower than that in normal subjects and at the same time significantly different from that in patients with iron deficiency anemia. EF concentration increased prior to PF concentration in patients with iron deficiency anemia who had been treated for a period of 1-8 weeks. EF concentration in patients with anemia of chronic diseases had a significant difference as compared with that in normal subjects and in patients with iron deficiency anemia, but EF concentration in those patients who were accompanied by iron deficiency was similar to that in patients with simple iron deficiency anemia. EF concentration in some iron overloaded patients (aplastic anemia, megaloblastic anemia, MDS etc.) was significantly higher than that in normal subjects. It was demonstrated that there was a good correlation between EF concentration and bone marrow sideroblastic iron in the rank correlation analysis of the iron indices in 135 patients (rs 0.893, P less than 0.01). PF concentration had the best correlation with marrow iron (rs 0.948, P less than 0.01).
Zhonghua Nei Ke Za Zhi 1990 Oct
PMID:[Evaluation of erythrocyte basic ferritin in the diagnosis of anemia]. 208

Basing on the analysis of five tests including serum ferritin, erythrocyte protoporphyrin, serum iron, total iron binding capacity and transferrin saturation in 92 anemic patients who were classified into iron deficient anemia (IDA) and non-iron deficient anemia by their bone marrow iron status, three models of combination of tests were designed by varying the test combination and diagnostic levels in model 1 and 2 and multiple regression analysis in model 3. The sensitivity and specificity for IDA were 93.7% and 93.1% respectively with the optimum scheme of combination of tests from model 2 in which serum ferritin has more weight than other tests. With the optimum scheme from the model 3 which was the discriminant function, the sensitivity and specificity were 93.3% and 100% respectively when the scheme tests the cases who are not included in the calculation of the function. It will decrease the number of false-positive or false-negative diagnosis due to the complex results of combination of test when the optimum combination of tests is used in the investigation of iron status and clinical work.
Zhonghua Nei Ke Za Zhi 1989 Mar
PMID:[Diagnosis of iron deficiency anemia with an optimum combination of tests]. 280 48

On the basis of clinical and laboratory data of 50 patients with adult onset Still's disease (AOSD), we strictly examined 4 diagnostic criteria adopted by different authors: criteria of Calabro, ARA, Medsger and Liu Gui-xin. Our result shows that Calabro's criteria has the best specificity (100%) and a higher diagnosis index (0.90) among the 4 criteria. Liu's criteria provides the best sensitivity (98%), but a lower specificity (86.9%) with a misdiagnosis rate of 14%. The rate of missed diagnosis with the ARA criteria is 35.7%. According to the present study, we recommend Liu's criteria for preliminary screen diagnosis, while Calabro's criteria for confirmation and differential diagnosis. Of special interest is that serum ferritin (SF) determination showed significantly higher level in 20 patients with AOSD (average 1194.5mg/L) than that in 19 patients with other rheumatic diseases (average 94mg/L, P < 0.001). AOSD patients with active disease have higher SF levels than patients with inactive disease (average 2742.9mg/L & 291.25mg/L, P < 0.001). So this test might be useful in diagnosis in AOSD and assessment of disease activity.
Zhonghua Nei Ke Za Zhi 1993 Sep
PMID:[Adult onset Still's disease: review of 50 cases and evaluation of diagnostic criteria]. 811 44

Recombinant human erythropoietin (r-HuEPO) was administered in 68 dialyzed patients (32 on acetate hemodialysis, 24 bicarbonate hemodialysis and 12 on hemo-filtration). The mean initial Hb 52.7 +/- 8.0g/L, Ht 19.4 +/- 2.2%, serum ferritin > 100ng/L. Each patients received r-HuEPO intravenously, at the dose of 300U/Kg/w for 6.2 +/- 4.3 months. Target range: Hb 100-120g/L, Ht 30-35%. After r-HuEPO treatment, blood transfusion was not needed for any of the patients, anemia was ameliorated with increase of Hb and Ht levels. It was found that the minimum effective dose of the r-HrEPO was 150-300U/Kg/w. We conclude that r-HuEPO is effective as treatment for the anemia of dialyzed patients. However, hypertension, clotted dialyzers and dialysis access thromboses were been developed in some patients after correction of anemia. There is now a general consensus that these side effects may be minimized if r-HuEPO is initially given in small doses with increments to avoid a too rapid correction of the anemia.
Zhonghua Nei Ke Za Zhi 1993 Feb
PMID:[Clinical studies of recombinant human erythropoietin in patients on long-term dialysis]. 840 23

Objective: To investigate the clinical features of macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE). Method: The clinical data of 15 patients with SLE-induced MAS diagnosed in Peking Union Medical College Hospital from July 2011 to December 2014 were retrospectively analyzed. Results: Fourteen patients were female. The average age was 28.07. When MAS occurred, the average duration of SLE was 20.47 months, and the average SLE disease activity index (SLEDAI) was 18.4. All 15 patients developed fever, hematocytopenia and impaired liver function in the course of MAS, while patients with splenomegaly, coagulation disorders and neuropsychiatric symptoms were 11, 14 and 8, respectively. All 15 patients presented leukocpenia and thrombocytopenia. Hypofibrinogenemia, elevated ferritin and hemophagocytosis in bone marrow were respectively observed in 7, 11 and 12 patients. Glucocorticoids were used in all patients, among whom eight received pulse methylprednisolone therapy. Thirteen patients were treated with immunosuppressants, including cyclosporine A, tacrolimus, cyclophosphamide and mycophemolate mofetil. Complete remission was achieved in 14 patients. One patient died of MAS. Conclusions: In patients with SLE, MAS was most commonly seen in young females with short SLE duration and active disease. Fever, splenomegaly, hematocytopenia, coagulation disorders and liver damage are the most remarkable clinical manifestations. Early diagnosis and intensive therapy are the key parts to improve clinical outcome.
Zhonghua Nei Ke Za Zhi 2016 Nov 01
PMID:[The clinical characteristics of macrophage activation syndrome secondary to systemic lupus erythematosus]. 2780 37

Objective: To explore the risk factors for lower extremity amputation in patients with diabetic foot. Methods: The clinical data of 1 771 patients with diabetic foot at the Air Force General Hospital of PLA from November 2001 to April 2015 were retrospectively analyzed. The patients were divided into the non-amputation and amputation groups. Within the amputation group, subjects were further divided into the minor and major amputation subgroups. Binary logistic regression analyses were used to assess the association between risk factors and lower extremity amputation. Results: Among 1 771 patients with diabetic foot, 323 of them (18.24%) were in the amputation group (major amputation: 41; minor amputation: 282) and 1 448 (81.76%) in the non-amputation group. Compared with non-amputation patients, those in the amputation group had a longer hospital stay and higher estimated glomerular filtration rate(eGFR)levels. Fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), C-reaction protein (CRP), ESR, ferritin, fibrinogen and WBC levels of the amputation group were higher, while hemoglobin albumin, transferrin, TC, TG, HDL-C and LDL-C were lower than those of the non-amputation group (all P<0.05). The proportion of hypertension(52.48% vs 59.98%), peripheral vascular disease (PAD)(68.11% vs 25.04%), and coronary heart disease(21.33% vs 28.71%)were different between the amputation and non-amputation groups (all P<0.05). Multivariable logistic regression analyses showed that Wagner's grade, PAD and CRP were the independent risk factors associated with lower extremity amputation in hospitalized patients with diabetic foot. Conclusion: Wagner's grade, ischemia of lower limbs and infection are closely associated with amputation of diabetic foot patients.
Zhonghua Nei Ke Za Zhi 2017 Jan 01
PMID:[Risk factors for lower extremity amputation in patients with diabetic foot]. 2805 19